‘King Keytruda’s reign continues.’ Investors aren’t wowed by a promising new lung cancer drug.
MarketWatchPaywall
Read Full Article at MarketWatch →Ad Slot — In-Article (728x90)
The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug
This is a summary. For the full story, read the original article at MarketWatch.
Original source: MarketWatch